ALDX (Aldeyra Therapeutics) Short-Term Debt: $15.30 Mil (As of Mar. 2026)


ALDX Aldeyra Therapeutics Inc ALDX
29 GF Score
Price $2.27
! 2 Warning Signs
View Full Analysis

What is Aldeyra Therapeutics Short-Term Debt?

Aldeyra Therapeutics ALDX -6.58% 29 Short-Term Debt is $15.30 Mil as of Mar. 2026. GuruFocus rates ALDX with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Aldeyra Therapeutics's Short-Term Debt for the quarter that ended in Mar. 2026 was $15.30 Mil.

Aldeyra Therapeutics's quarterly Short-Term Debt increased from Sep. 2025 ($15.20 Mil) to Dec. 2025 ($15.25 Mil) and increased from Dec. 2025 ($15.25 Mil) to Mar. 2026 ($15.30 Mil).

Aldeyra Therapeutics's annual Short-Term Debt declined from Dec. 2023 ($15.15 Mil) to Dec. 2024 ($0.03 Mil) but then increased from Dec. 2024 ($0.03 Mil) to Dec. 2025 ($15.25 Mil).

Aldeyra Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Aldeyra Therapeutics Short-Term Debt Related Terms

Aldeyra Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Aldeyra Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics Short-Term Debt Chart

Aldeyra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.91 15.15 0.03 15.25

Aldeyra Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 15.15 15.20 15.25 15.30
ALDX
29GF Score
Aldeyra Therapeutics Inc ALDX
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $15.30 Mil mean?
Aldeyra Therapeutics (ALDX) has a Short-Term Debt of $15.30 Mil as of Mar. 2026.
Is Aldeyra Therapeutics' Short-Term Debt too high?
Aldeyra Therapeutics' current Short-Term Debt is $15.30 Mil. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' Short-Term Debt compare to ONCY and VRCA?
Aldeyra Therapeutics' Short-Term Debt of $15.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Aldeyra Therapeutics's current Short-Term Debt is $15.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current Short-Term Debt of $15.30 Mil. The current Short-Term Debt is $15.30 Mil. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current Short-Term Debt is $15.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aldeyra Therapeutics Business Description

Other Exchanges 137:Germany
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score

Get the complete analysis for ALDX

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.27
Price